ORLANDO, Fla., Feb. 18,
2020 /PRNewswire/ -- IBM Watson Health (NYSE: IBM) today unveiled
its newest cloud-based technology IBM Study Advance at the 11th
Annual Summit for Clinical Ops Executives (SCOPE). The
data-driven, study design tool, is designed to optimize clinical
trial protocol design by merging automated access to real-world
patient population data, standardizing protocol template guidance
and providing a collaborative workspace designed to facilitate
efficiency.
On average, a single protocol amendment to a Phase III clinical
trial can result in approximately $500,000 (USD) in unplanned expenses and an
additional 61 days to the project timeline.1 IBM Study
Advance is designed to offer critical insights during the process
of study design to help reduce the number of amendments during
clinical trials. The tool is designed with an interface to
provide access to commercial and claims data from de-identified
patient profiles covering 89 million lives from multiple
employer-sponsored U.S. healthcare beneficiaries, as well as tools
to assess the impact of inclusion and exclusion criteria on the
eligible patient population.
"Currently, 80% of trials experience delays in
recruiting2 and one out of four amendments were
considered completely avoidable3," said Rob DiCicco, PharmD, Deputy Chief Health
Officer, IBM Watson Health. "Breakdowns in the clinical trial
process, including issues caused by study design decisions, may
potentially delay access to life-changing therapies for patients.
IBM Study Advance aims to remove the barriers in clinical
development to help researchers efficiently bring necessary
therapies to patients."
Study Advance's collaborative workspace is designed to allow
near real-time collaboration with study design team members who can
manage and assign the team to specific sections of the protocol.
The workspace is also designed to provide access to standard
protocol templates and version control capabilities with complete
traceability back to changes, aiming to reduce the average time
required to author a clinical trial protocol.
Experience Study Advance
For more information about IBM Study Advance, please visit the
website. Interested parties can also find more information at the
IBM Watson Health booth at the SCOPE conference located at booth
#317.
About IBM Watson Health
Watson Health is a business unit of IBM that is dedicated to the
development and implementation of cognitive and data-driven
technologies to advance health. Watson Health technologies
are tackling a wide range of the world's biggest health care
challenges, including cancer, diabetes, drug discovery and more.
Learn more at ibm.com/watson/health.
IBM Media Contact
Rachel Ford Hutman
External Relations
301-801-5540
Rachel.Hutman@ibm.com
1 Getz K. (2014). Improving protocol design
feasibility to drive drug development economics and
performance. International journal of environmental
research and public health, 11(5), 5069-80.
doi:10.3390/ijerph110505069
2
https://www.clinicalleader.com/doc/considerations-for-improving-patient-0001
3 Getz K. (2016). Acknowledging Cycle Time Impact from
Protocol Amendments. Applied Clinical Trials, 25(4).
Retrieved from
http://www.appliedclinicaltrialsonline.com/acknowledging-cycle-time-impact-protocol-amendments
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ibm-study-advance-designed-to-reduce-the-time-and-costs-associated-with-clinical-trials-301006222.html
SOURCE IBM